Bristol Myers Squibb stock holds firm as CAR-T pause and dividend yield draw investor attention

Published on 09/03/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock is trading in the mid-60 USD range with a dividend yield near 3.8 percent, while a cautious pause in autoimmune CAR-T enrollment and steady year-to-date gains shape the current risk-reward picture for investors.

Wissenschaftlerin im Schutzanzug blickt durch ein Fluoreszenzmikroskop auf leuchtende Zellkulturen in einem sterilen Onkologielabor — Bristol-Myers Squibb US0897961004 zeigt Onkologieforscherin am Mikroskop mit leuchtenden Zellkulturen im sterilen Labor, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US0897961004) is trading around 66.9 USD per share on the New York Stock Exchange as of September 2, 2026, implying a market capitalization in the area of 136.7 billion USD according to recent market data, with the shares up about 23.7 percent year to date from a starting level of 53.93 USD in 2026.

Clinical pause in CAR-T trials shapes risk discussion

A key short-term catalyst is Bristol Myers Squibb's decision to voluntarily pause enrollment in its autoimmune trials evaluating the experimental CAR-T therapy zola-cel after transient, reversible inflammatory events were detected during routine safety surveillance, as reported on September 2, 2026 by PharmExec.

According to the PharmExec coverage, Bristol Myers Squibb has paused new patient enrollment but continues the ongoing studies, describing the move as taken out of caution while the company reviews clinical data across the zola-cel program.

Dividend yield and year-to-date performance

For income-focused investors, Bristol Myers Squibb's dividend profile is an important part of the story. A same-day analysis on September 2, 2026 highlights that the company has increased its quarterly dividend for 17 straight years, including a 1.6 percent raise in 2026 to 0.63 USD per share, which translates into a dividend yield of about 3.76 percent at the current share price.

As outlined by a recent dividend-focused article, the combination of a forward price-to-earnings ratio below 10 and a yield near 3.8 percent positions Bristol Myers Squibb as one of the more attractively valued large-cap pharmaceutical names in the current market.

MarketBeat data as of September 2, 2026 further shows that Bristol Myers Squibb stock has risen from 53.93 USD at the start of 2026 to around 66.72 USD, a gain of 23.7 percent, underscoring that the shares have delivered solid price appreciation alongside the dividend income so far this year.

Go deeper

More on Bristol Myers Squibb stock

Read additional news and background on Bristol Myers Squibb stock, including corporate actions and market reactions, in the dedicated ISIN overview.

Bristol Myers Squibb stock overview Investor Relations

Representative product: Camzyos in cardiology

Beyond the current CAR-T headlines, one of Bristol Myers Squibb's notable recent products is the heart-failure drug Camzyos, which targets obstructive hypertrophic cardiomyopathy and has been a focus of clinical and commercial discussions in 2026, with positive data viewed as a contributor to sentiment around the stock even though detailed revenue figures for the latest quarter are not yet highlighted in the same-day sources.

Stock price and trading venue

As of September 2, 2026, Bristol Myers Squibb stock is quoted at about 66.90 USD per share on the New York Stock Exchange according to a recent price snapshot, placing the shares in the mid-60 USD range and reflecting a steady performance in the broader Wall Street environment where indexes have reclaimed some shine after recent volatility.